10/2/2009

GlaxoSmithKline's kidney cancer drug pazopanib was linked to the death of three patients who developed liver damage while participating in a clinical trial, the FDA warned. The report was issued ahead of an FDA panel meeting on pazopanib Monday.

Related Summaries